David G. Pfister, MD, on Supportive Care in Head and Neck Cancers: Multidisciplinary Management
NCCN 2021 Virtual Annual Conference
David G. Pfister, MD, of Memorial Sloan Kettering Cancer Center, discusses the many considerations when caring for patients with head and neck cancers, such as dental and nutritional issues; side effects from radiation, including necrosis of the bone; oral health; problems with speech; and the concerns of younger patients who may have to cope with the sequelae of treatment such as altered function or disfigurement for years to come.
The ASCO Post Staff
Jennifer R. Brown, MD, PhD, of Dana-Farber Cancer Institute, discusses treatment choices for patients with relapsed or refractory CLL/SLL, when to stop therapy due to adverse events, BTK inhibitors and their second-generation counterparts, the need for ways to manage disease progression on novel drugs, and minimal residual disease as a predictor of response.
The ASCO Post Staff
Robert Winn, MD, of the Virginia Commonwealth University Massey Cancer Center, discusses the creation of a health equity report card to track how institutions are dealing with disparities in oncology care, ways to recognize bias in care, and adding health equity experts to guideline panels and other advisory groups.
The ASCO Post Staff
Lori J. Wirth, MD, of Massachusetts General Hospital Cancer Center, discusses the common molecular alterations across thyroid cancer subtypes; targeted treatments for BRAF V600E–mutant, NTRK–fusion positive, and RET–altered disease; and optimal therapies for patients with multiple types of thyroid cancer.
The ASCO Post Staff
Gabrielle A. Zecha, PA-C, MHA, of Fred Hutchinson Cancer Research Center and Seattle Cancer Care Alliance, and Aaron Begue, MS, RN, NP-C, OCN, of Memorial Sloan Kettering Cancer Center, discuss how advanced practice providers are recruited and trained, ways to retain these valuable health-care professionals in the face of burnout, metrics to measure their productivity, and their future role in cancer care.
The ASCO Post Staff
Melinda L. Telli, MD, of Stanford Cancer Institute, discusses highlights of the new NCCN Clinical Practice Guidelines in Oncology®, including nonanthracycline, taxane-based regimens as preferred treatments for patients with HER2-positive breast cancer; newly approved combination therapies such as tucatinib plus capecitabine plus trastuzumab, margetuximab plus chemotherapy, and neratinib plus capecitabine; and recommendations for third line and beyond.
